Literature DB >> 25925726

Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease.

Adrian G Todd1, Jessica A McElroy1, Robert W Grange2, David D Fuller3, Glenn A Walter4, Barry J Byrne1, Darin J Falk1.   

Abstract

OBJECTIVE: We have recently reported on the pathology of the neuromuscular junction (NMJ) in Pompe disease, reflecting disruption of neuronal and muscle homeostasis as a result of glycogen accumulation. The aim of this study was to examine how the alteration of NMJ physiology contributes to Pompe disease pathology; we performed molecular, physiological, and histochemical analyses of NMJ-related measures of the tibialis anterior muscles of young-, mid-, and late-stage alpha-glucosidase (GAA)-deficient mice.
METHODS: We performed intramuscular injection of an adeno-associated virus (AAV)9 vector expressing GAA (AAV9-hGAA) into the tibialis anterior muscle of Gaa(-/-) mice at early, mid, and severe pathological time points. We analyzed expression of NMJ-related genes, in situ muscle force production, and clearance of glycogen in conjunction with histological assessment of the NMJ.
RESULTS: Our data demonstrate that AAV9-hGAA is able to replace GAA to the affected tissue and modify AChR mRNA expression, muscle force production, motor endplate area, and innervation status. Importantly, the degree of restoration for these outcomes is limited by severity of disease. Early restoration of GAA activity was most effective, whereas late correction of GAA expression was not effective in modifying parameters reflecting NMJ structure and function nor in force restoration despite resolution of glycogen storage in muscle.
INTERPRETATION: Our data provide new mechanistic insight into the pathology of Pompe disease and suggest that early systemic correction to both neural and muscle tissues may be essential for successful correction of neuromuscular function in Pompe disease. Ann Neurol 2015;78:222-234.
© 2015 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25925726      PMCID: PMC4520217          DOI: 10.1002/ana.24433

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  48 in total

1.  Diagnostic criteria for late-onset (childhood and adult) Pompe disease.

Authors: 
Journal:  Muscle Nerve       Date:  2009-07       Impact factor: 3.217

2.  Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors.

Authors:  Cathryn Mah; Christina A Pacak; Kerry O Cresawn; Lara R Deruisseau; Sean Germain; Melissa A Lewis; Denise A Cloutier; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2007-01-23       Impact factor: 11.454

3.  Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I).

Authors:  Friedrich Metzger; Waseem Sajid; Stefanie Saenger; Christian Staudenmaier; Chris van der Poel; Bettina Sobottka; Angelika Schuler; Mandy Sawitzky; Raphael Poirier; Dietrich Tuerck; Eginhard Schick; Andreas Schaubmar; Friederike Hesse; Kurt Amrein; Hansruedi Loetscher; Gordon S Lynch; Andreas Hoeflich; Pierre De Meyts; Hans-Joachim Schoenfeld
Journal:  J Biol Chem       Date:  2011-04-01       Impact factor: 5.157

4.  The effect of subacute denervation on the electrical anisotropy of skeletal muscle: implications for clinical diagnostic testing.

Authors:  Mohammad A Ahad; Pushpa Narayanaswami; Lora J Kasselman; Seward B Rutkove
Journal:  Clin Neurophysiol       Date:  2010-02-11       Impact factor: 3.708

5.  Site-specific Mtm1 mutagenesis by an AAV-Cre vector reveals that myotubularin is essential in adult muscle.

Authors:  Romain Joubert; Alban Vignaud; Mickaël Le; Christelle Moal; Nadia Messaddeq; Anna Buj-Bello
Journal:  Hum Mol Genet       Date:  2013-02-05       Impact factor: 6.150

6.  Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice.

Authors:  Robin J Ziegler; Scott D Bercury; Jonathan Fidler; Michael A Zhao; Joseph Foley; Tatyana V Taksir; Susan Ryan; Bradley L Hodges; Ronald K Scheule; Lamya S Shihabuddin; Seng H Cheng
Journal:  Hum Gene Ther       Date:  2008-06       Impact factor: 5.695

Review 7.  Pompe's disease.

Authors:  Ans T van der Ploeg; Arnold J J Reuser
Journal:  Lancet       Date:  2008-10-11       Impact factor: 79.321

8.  Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease.

Authors:  Darin J Falk; Cathryn S Mah; Meghan S Soustek; Kun-Ze Lee; Mai K Elmallah; Denise A Cloutier; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2013-06-04       Impact factor: 11.454

9.  B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study.

Authors:  M Corti; Me Elder; Dj Falk; L Lawson; Bk Smith; S Nayak; Tj Conlon; N Clément; K Erger; E Lavassani; M Green; Pa Doerfler; Rw Herzog; Bj Byrne
Journal:  Mol Ther Methods Clin Dev       Date:  2014       Impact factor: 6.698

10.  A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy.

Authors:  Giancarlo Parenti; Simona Fecarotta; Giancarlo la Marca; Barbara Rossi; Serena Ascione; Maria Alice Donati; Lucia Ovidia Morandi; Sabrina Ravaglia; Anna Pichiecchio; Daniela Ombrone; Michele Sacchini; Maria Barbara Pasanisi; Paola De Filippi; Cesare Danesino; Roberto Della Casa; Alfonso Romano; Carmine Mollica; Margherita Rosa; Teresa Agovino; Edoardo Nusco; Caterina Porto; Generoso Andria
Journal:  Mol Ther       Date:  2014-07-23       Impact factor: 11.454

View more
  26 in total

Review 1.  Pompe Disease: From Basic Science to Therapy.

Authors:  Lara Kohler; Rosa Puertollano; Nina Raben
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

2.  Spot light on skeletal muscles: optogenetic stimulation to understand and restore skeletal muscle function.

Authors:  Tobias van Bremen; Thorsten Send; Philipp Sasse; Tobias Bruegmann
Journal:  J Muscle Res Cell Motil       Date:  2017-09-16       Impact factor: 2.698

Review 3.  Progress and challenges of gene therapy for Pompe disease.

Authors:  Giuseppe Ronzitti; Fanny Collaud; Pascal Laforet; Federico Mingozzi
Journal:  Ann Transl Med       Date:  2019-07

Review 4.  Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.

Authors:  Barry J Byrne; David D Fuller; Barbara K Smith; Nathalie Clement; Kirsten Coleman; Brian Cleaver; Lauren Vaught; Darin J Falk; Angela McCall; Manuela Corti
Journal:  Ann Transl Med       Date:  2019-07

5.  Small-hairpin RNA and pharmacological targeting of neutral sphingomyelinase prevent diaphragm weakness in rats with heart failure and reduced ejection fraction.

Authors:  Philip D Coblentz; Bumsoo Ahn; Linda F Hayward; Jeung-Ki Yoo; Demetra D Christou; Leonardo F Ferreira
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-01-31       Impact factor: 5.464

6.  Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.

Authors:  Allison M Keeler; Marina Zieger; Sophia H Todeasa; Angela L McCall; Jennifer C Gifford; Samantha Birsak; Sourav R Choudhury; Barry J Byrne; Miguel Sena-Esteves; Mai K ElMallah
Journal:  Hum Gene Ther       Date:  2018-07-25       Impact factor: 5.695

7.  Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease.

Authors:  Manuela Corti; Cristina Liberati; Barbara K Smith; Lee Ann Lawson; Ibrahim S Tuna; Thomas J Conlon; Kirsten E Coleman; Saleem Islam; Roland W Herzog; David D Fuller; Shelley W Collins; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2017-12       Impact factor: 5.032

Review 8.  Aldehyde dehydrogenase 2 in aplastic anemia, Fanconi anemia and hematopoietic stem cells.

Authors:  Lauren D Van Wassenhove; Daria Mochly-Rosen; Kenneth I Weinberg
Journal:  Mol Genet Metab       Date:  2016-07-15       Impact factor: 4.797

9.  Transcriptome assessment of the Pompe (Gaa-/-) mouse spinal cord indicates widespread neuropathology.

Authors:  S M F Turner; D J Falk; B J Byrne; D D Fuller
Journal:  Physiol Genomics       Date:  2016-09-09       Impact factor: 3.107

10.  Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease.

Authors:  Phillip A Doerfler; Adrian G Todd; Nathalie Clément; Darin J Falk; Sushrusha Nayak; Roland W Herzog; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2016-01       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.